침습적 감염증에서 Glycopeptides 계열 항생제의 적절한 투약과 치료적 약물 농도 평가

키워드

참고문헌 (92)

1. Butler MS, "Glycopeptide antibiotics : back to the future", J Antibiot(Tokyo), 67, pp.631~644 (2014)
2. Rubinstein E, "Vancomycin revisited-60 years later", Front Public Health, 2, pp.217~ (2014)
3. Choi WS, "Textbook of guideposts to antimicrobial", pp.298~309 (2016), Koonja Publishing Inc
4. McCormick MH, "Vancomycin, a new antibiotic. I. Chemical and biologic properties", Antibiot Annu, 3, pp.606~611 (1955)
5. Bardone MR, "Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. II. Extraction and chemical characterization", J Antibiot(Tokyo), 31, pp.170~177 (1978)
6. Svetitsky S, "Comparative efficacy and safety of vancomycin versus teicoplanin : systematic review and meta-analysis", Antimicrob Agents Chemother, 53, pp.4069~4079 (2009)
7. Judice JK, "Semi-synthetic glycopeptide antibacterials", Bioorg Med Chem Lett, 13, pp.4165~4168 (2003)
8. Candiani G, "In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic", J Antimicrob Chemother, 44, pp.179~192 (1999)
9. Bouza E, "Oritavancin : a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains", Int J Antimicrob Agents, 36, pp.401~407 (2010)
10. Giuliano C, "Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections", Expert Rev Anti Infect Ther, 8, pp.95~106 (2010)
11. Ramos-Martín V, "Pharmacodynamics of teicoplanin against MRSA", J Antimicrob Chemother, 72, pp.3382~3389 (2017)
12. Rybak MJ, "Vancomycin therapeutic guidelines : a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists", Clin Infect Dis, 49, pp.325~327 (2009)
13. Rybak MJ, "Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections : a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists", Am J Health Syst Pharm, 77, pp.835~864 (2020)
14. Outman WR, "Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses", Antimicrob Agents Chemother, 34, pp.2114~2117 (1990)
15. Kim SH, "Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring : not too high for adverse event, not too low for treatment efficacy", Eur J Clin Microbiol Infect Dis, 38, pp.2113~2120 (2019)
16. Matzke GR, "Clinical pharmacokinetics of vancomycin", Clin Pharmacokinet, 11, pp.257~282 (1986)
17. Ulldemolins M, "The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients", Clin Pharmacokinet, 50, pp.99~110 (2011)
18. Rybak MJ., "The pharmacokinetic and pharmacodynamic properties of vancomycin", Clin Infect Dis., 42(Suppl 1), pp.S35~S39 (2006)
19. Larsson AJ, "The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions", J Antimicrob Chemother, 38, pp.589~597 (1996)
20. Knudsen JD, "Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model", Antimicrob Agents Chemother, 41, pp.1910~1915 (1997)
21. Moise-Broder PA, "Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections", Clin Pharmacokinet, 43, pp.925~942 (2004)
22. Kullar R, "Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia : support for consensus guidelines suggested targets", Clin Infect Dis, 52, pp.975~981 (2011)
23. Brown J, "Vancomycin AUC24", MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization, 2012, pp.56, 634~638
24. Holmes NE, "Vancomycin AUC", MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia, 2013, pp.57, 1654~1663
25. Jumah MTB, "Pharmacokinetic", pharmacodynamic determinants of vancomycin efficacy in Enterococcal bacteremia, 2018, pp.62, e01602~e01617
26. Nakakura I, "Association between vancomycin pharmacokinetic", pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium : a single-center retrospective study, 2019, pp.5, 8~
27. van Hal SJ, "Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15and 20 milligrams per liter", Antimicrob Agents Chemother, 57, pp.734~744 (2013)
28. Suzuki Y, "Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia", Chemotherapy, 58, pp.308~312 (2012)
29. Lodise TP, "Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients", Clin Infect Dis, 49, pp.507~514 (2009)
30. Park SJ, "Evaluation of risk factors for vancomycin-induced nephrotoxicity", Int J Clin Pharm, 40, pp.1328~1334 (2018)
31. Pai MP, "Innovative approaches to optimizing the delivery of vancomycin in individual patients", Adv Drug Deliv Rev, 77, pp.50~57 (2014)
32. Neely MN, "Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing", Antimicrob Agents Chemother, 62, pp.e02042~ (2018)
33. Turner RB, "Review and validation of bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve incritically ill patients", Pharmacotherapy, 38, pp.1174~1183 (2018)
34. Drennan P, "Bayesian therapeutic drug monitoring software : past, present and future", Int J Pharmacokinet, 3, pp.109~114 (2018)
35. Begg EJ, "A suggested approach to once-daily aminoglycoside dosing", Br J Clin Pharmacol, 39, pp.605~609 (1995)
36. Diaz R, "Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis", Clin Microbiol Infect, 24, pp.97~104 (2018)
37. Kruzel MC, "Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus", J Clin Microbiol, 49, pp.2272~2273 (2011)
38. Hsu DI, "Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus(MRSA)infections", Int J Antimicrob Agents, 32, pp.378~385 (2008)
39. Steinmetz T, "Association of vancomycin serum concentrations with efficacy in patients with MRSA infections : a systematic review and meta-analysis", Clin Microbiol Infect, 21, pp.665~673 (2015)
40. Clark L, "Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections", Ther Drug Monit, 41, pp.483~488 (2019)
41. Neely MN, "Are vancomycin trough concentrations adequate for optimal dosing?", Antimicrob Agents Chemother, 58, pp.309~316 (2014)
42. Liang X, "A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring", Clin Infect Dis., 67, pp.S249~S255
43. Gilbert DN, "The sanford guide to antimicrobial therapy 2019: 50 years: 1969-2019", pp.234~249 (2019), Antimicrobial Therapy
44. Kim SH, "Weight-based vancomycin loading strategy may not improve achievement of optimal vancomycin concentration in patients with preserved renal function", J Chemother, 33, pp.56~61 (2021)
45. Baptista JP, "Augmented renal clearance in septic patients and implications for vancomycin optimisation", Int J Antimicrob Agents, 39, pp.420~423 (2012)
46. Crass RL, "Dosing vancomycin in the super obese : less is more", J Antimicrob Chemother, 73, pp.3081~3086 (2018)
47. Wysocki M, "Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections : prospective multicenter randomized study", Antimicrob Agents Chemother, 45, pp.2460~2467 (2001)
48. Vuagnat A, "High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion", J Clin Pharm Ther, 29, pp.351~357 (2004)
49. Hanrahan T, "Vancomycin-associated nephrotoxicity : a meta-analysis of administration by continuous versus intermittent infusion", Int J Antimicrob Agents, 46, pp.249~253 (2015)
50. Verrall AJ, "Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections", J Antimicrob Chemother, 67, pp.2970~2973 (2012)
51. Baker DS, "Compatibility and stability of cefotaxime, vancomycin, and ciprofloxacin in antibiotic lock solutions containing heparin", Int J Pharm Compd, 14, pp.346~349 (2010)
52. Choi YC, "Intravenous vancomycin associated with the development of nephrotoxicity in patients with class iii obesity", Ann Pharmacother, 51, pp.937~944 (2017)
53. Bauer LA, "Vancomycin dosing in morbidly obese patients", Eur J Clin Pharmacol, 54, pp.621~625 (1998)
54. Levin D, "Pharmacist and Physician Collaborative Practice Model Improves Vancomycin Dosing in an Intensive Care Unit", Int J Clin Med, 7, pp.675~684 (2016)
55. Mahmoud LB, "Optimization of therapeutic drug monitoring of vancomycin in patients with chronic hemodialysis", Clin Nephrol, 88, pp.198~204 (2017)
56. Fu CF, "The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia", PLoS One, 13, pp.e0193585~ (2018)
57. Bierman MH, "Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients", J Dial, 4, pp.179~184 (1980)
58. Crawford BS, "Once-weekly vancomycin for patients receiving high-flux hemodialysis", Am J Health Syst Pharm, 65, pp.1248~1253 (2008)
59. De Bock V, "Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration", Nephrol Dial Transplant, 4, pp.635~639 (1989)
60. Mason NA, "Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers : post-dialysis versus intradialytic administration", Clin Nephrol, 60, pp.96~104 (2003)
61. Pallotta KE, "Vancomycin use in patients requiring hemodialysis : a literature review", Semin Dial, 21, pp.63~70 (2008)
62. Pollard TA, "Vancomycin redistribution : dosing recommendations following high-flux hemodialysis", Kidney Int, 45, pp.232~237 (1994)
63. Covajes C, "Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy", Int J Antimicrob Agents, 41, pp.261~266 (2013)
64. Yang CJ, "Effect of extracorporeal membrane oxygenation on the new vancomycin dosing regimen in critically ill patients receiving continuous venovenous hemofiltration", Ther Drug Monit, 40, pp.310~314 (2018)
65. Park SJ, "Trough concentrations of vancomycin in patients undergoing extracorporeal membrane oxygenation", PLoS One, 10, pp.e0141016~ (2015)
66. Choi R, "A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea", Infect Drug Resist, 12, pp.2163~2173 (2019)
67. Jung Y, "Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia", Int J Antimicrob Agents, 43, pp.179~183 (2014)
68. Bernareggi A, "Teicoplanin metabolism in humans", Antimicrob Agents Chemother, 36, pp.1744~1749 (1992)
69. Harding I, "Comparative pharmacokinetics of teicoplanin and vancomycin", J Chemother., 12(Suppl 5), pp.15~20 (2000)
70. Craig WA, "Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid", Infect Dis Clin North Am, 17, pp.479~501 (2003)
71. Kuti JL, "Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil", Clin Microbiol Infect, 14, pp.116~123 (2008)
72. Matsumoto K, "Pharmacokinetic", pharmacodynamic analysis of teicoplanin in patients with MRSA infections, 2016, pp.8, 15~18
73. Hagihara M, "Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus", J Infect Chemother, 18, pp.10~16 (2012)
74. Matsumoto K, "Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days : a retrospective study in patients with MRSA infections", J Infect Chemother, 16, pp.193~199 (2010)
75. Harding I, "Teicoplanin therapy for Staphylococcus aureus septicaemia : relationship between pre-dose serum concentrations and outcome", J Antimicrob Chemother, 45, pp.835~841 (2000)
76. Greenberg RN, "Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin", Antimicrob Agents Chemother, 34, pp.2392~2397 (1990)
77. 안병진, "Teicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients with Neutropenic Fever", Yonsei Medical Journal, 52(4), pp.616~623 (2011), 연세대학교의과대학
78. Nakamura A, "Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections", J Infect Chemother, 21, pp.449~455 (2015)
79. Sato M, "Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level", J Infect Chemother, 12, pp.185~189 (2006)
80. Wilson AP, "Clinical pharmacokinetics of teicoplanin", Clin Pharmacokinet, 39, pp.167~183 (2000)
81. Carver PL, "Pharmacokinetics of single-and multiple-dose teicoplanin in healthy volunteers", Antimicrob Agents Chemother, 33, pp.82~86 (1989)
82. Henry P, "Handbook of drugs in intensive care: an A-Z guide", pp.276~ (2019), Cambridge University Press
83. "Teicoplanin" (2017)[URL]
84. Papaioannou MG, "Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis", Int J Antimicrob Agents, 19, pp.233~236 (2002)
85. Bonati M, "Pharmacokinetics of a single intravenous dose of teicoplanin in subjects with various degrees of renal impairment", J Antimicrob Chemother., 21(Suppl A), pp.29~37 (1988)
86. Wolter K, "Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis", Clin Nephrol, 42, pp.389~397 (1994)
87. Thalhammer F, "Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes", Wien Klin Wochenschr, 109, pp.362~365 (1997)
88. Shiraishi Y, "Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration : screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin", Anaesth Intensive Care, 40, pp.442~449 (2012)
89. Yagasaki K, "Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration", Intensive Care Med, 29, pp.2094~2095 (2003)
90. Lim SK, "High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration", Hemodial Int, 23, pp.69~76 (2019)
91. Pea F, "Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy", Clin Pharmacokinet, 46, pp.997~1038 (2007)
92. 나소연, "Therapeutic Drug Concentrations of Teicoplanin in Clinical Settings", Infection and Chemotherapy, 46(1), pp.35~41 (2014), 대한감염학회[DOI]

관련 논문AI추천